$BTCBitcoin closes above 50-week moving average, signaling potential bear market endSep 21, 2026
METAFacebook and Instagram restore service after brief US outageSep 21, 2026
ENERGYButker's 40-yarder gives Chiefs 33-30 overtime win over ColtsSep 21, 2026
MACRONew Zealand Navy vessels transit Taiwan StraitSep 21, 2026
$ARBStandard Chartered projects 70x Arbitrum price increase by 2030Sep 21, 2026
NVDANvidia targets $400 next year on 70% revenue growthSep 21, 2026
EARNINGS$685,000 prize package crowns history-making Miss USA Justus KelleySep 19, 2026
REGULATORYThirty years on air, Fox News anchor Trace Gallagher says the hardest parenting skill is knowing when to stop talkingSep 19, 2026
$BTCBitcoin closes above 50-week moving average, signaling potential bear market endSep 21, 2026
METAFacebook and Instagram restore service after brief US outageSep 21, 2026
ENERGYButker's 40-yarder gives Chiefs 33-30 overtime win over ColtsSep 21, 2026
MACRONew Zealand Navy vessels transit Taiwan StraitSep 21, 2026
$ARBStandard Chartered projects 70x Arbitrum price increase by 2030Sep 21, 2026
NVDANvidia targets $400 next year on 70% revenue growthSep 21, 2026
EARNINGS$685,000 prize package crowns history-making Miss USA Justus KelleySep 19, 2026
REGULATORYThirty years on air, Fox News anchor Trace Gallagher says the hardest parenting skill is knowing when to stop talkingSep 19, 2026

Eli Lilly posts $23 billion Q2 as Mounjaro, Zepbound carry GLP-1 lead over Viking Therapeutics

$23 billion in second-quarter revenue, a 48% year-over-year gain reported by Eli Lilly (NYSE: LLY), anchors the company's case as the GLP-1 market's commercial leader. The math reconciles: tirzepatide generated $14.8 billion across its two…

By Lucia Moretti·Aug 8, 2026·2 min read·deals·LLY
Share
© 2026 NewsMeter